Although sympathetic overactivity modulated by H4R represents a hallmark feature of refractory hypertension,[3] our experimental evidence suggests that H4R does not directly drive hypertension pathogenesis, yet remains a promising therapeutic target. This evidence concerns the gene HRH4 and Hypertension.